- Home
- FRO vs MRUS Comparison
FRO vs MRUS Comparison
Compare FRO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRO
- MRUS
- Stock Information
- Founded
- FRO 1985
- MRUS 2003
- Country
- FRO Cyprus
- MRUS Netherlands
- Employees
- FRO N/A
- MRUS N/A
- Industry
- FRO Marine Transportation
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- FRO Consumer Discretionary
- MRUS Health Care
- Exchange
- FRO Nasdaq
- MRUS Nasdaq
- Market Cap
- FRO 5.2B
- MRUS 5.1B
- IPO Year
- FRO N/A
- MRUS 2016
- Fundamental
- Price
- FRO $23.60
- MRUS $94.91
- Analyst Decision
- FRO Strong Buy
- MRUS Buy
- Analyst Count
- FRO 3
- MRUS 18
- Target Price
- FRO $25.00
- MRUS $93.72
- AVG Volume (30 Days)
- FRO 2.6M
- MRUS 5.3M
- Earning Date
- FRO 11-26-2025
- MRUS 10-31-2025
- Dividend Yield
- FRO 7.56%
- MRUS N/A
- EPS Growth
- FRO N/A
- MRUS N/A
- EPS
- FRO 1.07
- MRUS N/A
- Revenue
- FRO $1,823,905,000.00
- MRUS $56,228,000.00
- Revenue This Year
- FRO N/A
- MRUS $47.25
- Revenue Next Year
- FRO $19.94
- MRUS N/A
- P/E Ratio
- FRO $22.77
- MRUS N/A
- Revenue Growth
- FRO N/A
- MRUS 59.77
- 52 Week Low
- FRO $12.40
- MRUS $33.19
- 52 Week High
- FRO $24.63
- MRUS $95.06
- Technical
- Relative Strength Index (RSI)
- FRO 55.42
- MRUS 81.71
- Support Level
- FRO $22.47
- MRUS $94.40
- Resistance Level
- FRO $24.63
- MRUS $95.02
- Average True Range (ATR)
- FRO 0.74
- MRUS 0.32
- MACD
- FRO 0.06
- MRUS -0.91
- Stochastic Oscillator
- FRO 69.08
- MRUS 81.10
About FRO Frontline Plc
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.